9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
Company profile
Ticker
NMTRQ
Exchange
Website
CEO
Sandeep Laumas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INNOVATE BIOPHARMACEUTICALS, INC., Monster Digital, Inc., Tandon Digital, Inc.
SEC CIK
Corporate docs
Subsidiaries
Naia Rare Diseases, LLC • RDD Pharma Ltd. ...
NMTRQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
8 Sep 23
8-K
Entry into a Material Definitive Agreement
18 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jun 23
8-K
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
30 May 23
8-K
Other Events
22 May 23
PRE 14A
Preliminary proxy
19 May 23
8-K
Entry into a Material Definitive Agreement
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
Latest ownership filings
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
144
Notice of proposed sale of securities
21 Jul 23
144
Notice of proposed sale of securities
19 Jul 23
144
Notice of proposed sale of securities
21 Apr 23
4
Bethany Sensenig
21 Apr 23
4
Mark A Sirgo
31 Mar 23
4
YEHUDA MICHAEL RICE
31 Mar 23
4
LORIN K JOHNSON
31 Mar 23
4
Michael T. Constantino
31 Mar 23
4
Samantha Ventimiglia
31 Mar 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.62 mm | 7.62 mm | 7.62 mm | 7.62 mm | 7.62 mm | 7.62 mm |
Cash burn (monthly) | 7.35 mm | 2.47 mm | 4.62 mm | 3.86 mm | 3.25 mm | 3.10 mm |
Cash used (since last report) | 94.42 mm | 31.73 mm | 59.42 mm | 49.65 mm | 41.78 mm | 39.90 mm |
Cash remaining | -86.79 mm | -24.10 mm | -51.80 mm | -42.03 mm | -34.15 mm | -32.27 mm |
Runway (months of cash) | -11.8 | -9.8 | -11.2 | -10.9 | -10.5 | -10.4 |
Institutional ownership, Q2 2023
71.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 6 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 2.04 bn |
Total shares | 10.37 mm |
Total puts | 200.00 |
Total calls | 504.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Capital Point | 7.30 mm | $6.13 mm |
Sabby Management | 1.04 mm | $697.83 mm |
Adage Capital Partners GP, L.L.C. | 650.00 k | $436.80 mm |
Vanguard | 619.83 k | $416.53 mm |
Laurion Capital Management | 218.71 k | $146.97 mm |
BLK Blackrock | 167.95 k | $112.86 mm |
Geode Capital Management | 108.82 k | $73.13 mm |
STT State Street | 50.91 k | $34.21 mm |
ODonnell Financial Services | 43.41 k | $29.17 mm |
Commonwealth Equity Services | 37.91 k | $25.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Apr 23 | Bethany Sensenig | Common stock | Sell | Dispose S | No | No | 1.21 | 9,100 | 11.01 k | 41,077 |
29 Mar 23 | Samantha Ventimiglia | Common Stock | Grant | Acquire A | No | No | 0 | 7,885 | 0.00 | 7,885 |
29 Mar 23 | Michael T. Constantino | Common Stock | Grant | Acquire A | No | No | 0 | 7,885 | 0.00 | 10,911 |
29 Mar 23 | Johnson Lorin K | Common Stock | Grant | Acquire A | No | No | 0 | 7,885 | 0.00 | 12,125 |
29 Mar 23 | Yehuda Michael Rice | Common Stock | Grant | Acquire A | No | No | 0 | 7,885 | 0.00 | 7,885 |